Remove Disease Remove Doctors Remove Molecular Biology Remove Research
article thumbnail

Meet the researcher: Dr Stephen Jones

Drug Discovery World

DDW’s Diana Spencer meets Dr Stephen Jones, Research Professor and Group Leader at the EMBL Partnership Institute for Genome Editing Technologies at Vilnius University’s Life Sciences Center. SJ: I lead a research group at the EMBL Partnership Institute in Vilnius, Lithuania. SJ: CRISPR is the obvious one.

Research 147
article thumbnail

How organoids can redefine pre-clinical research

Drug Target Review

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. The derived drug was given to both patients, to which researchers report the patients saw significant improvement.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount.

article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD.

Science 130
article thumbnail

Precision Medicine – it’s not just for oncology anymore

The Pharma Data

Researchers are also using sophisticated machine learning and artificial intelligence to illuminate predictive relationships from highly complex and multi-modal data, including clinical, molecular, and digital data. These analytical tools are giving teams a look at diseases at a digital pathology level. Source link.

article thumbnail

Mediating BRAF-mutant melanoma resistance

Drug Target Review

Her research focus is on epigenetic regulation of melanoma and other cancers as well as wound healing, ageing biology and the development of novel epigenetic therapies targeting cancers and skin diseases and she is the owner of 15 issued and pending patents relevant to her research. Dr Alani received her M.D.

article thumbnail

The democratisation of cell and gene therapy

Drug Discovery World

Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. DNA purification “Plasmid DNA is an incredibly important part of molecular biology”, says Hummersone.

Therapies 273